home / stock / pfe / pfe articles

PFE Articles, Pfizer Inc. - From 05/20/24

Stock Information
Company Name: Pfizer Inc.
Stock Symbol: PFE
Market: NYSE
Website: pfizer.com
Menu
PFE PFE Quote PFE Short PFE News PFE Articles PFE Message Board
Get PFE Alerts

News, Short Squeeze, Breakout and More Instantly...
Pfizer Wins $107.5M Verdict Against AstraZeneca Over Cancer Drug Patent Dispute | Benzinga

A Delaware federal jury has determined that AstraZeneca Plc (NASDAQ:AZN) must pay Pfizer Inc (NYSE:PFE) $107.5 million in ...
Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch | Benzinga

President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA)...

4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly | Benzinga

The obesity market has garnered much interest lately, ever since Novo Nordisk (NYSE: NVO) received FDA approval for its obesity drug Wegovy in 2021...

European Patent Office Sides with Moderna In COVID-19 Vaccine Patent Dispute With Pfizer/BioNTech | Benzinga

Moderna Inc (NASDAQ:MRNA) has reportedly achieved a significant victory at the European Patent Office (EPO) in its ongoing legal battle with&n...
GSK Completely Exits Sensodyne Toothpaste Maker Haleon In $1.6B Sale | Benzinga

GSK plc (NYSE:GSK) confirmed the sale of 385.3 million shares in Haleon plc (NYSE:HLN) for $1.58 billion. The shares represented around 4.2% o...

Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game | Benzinga

On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a...

Pfizer Settles Zantac Lawsuits, Agrees To $250M Settlement To Reduce Liability: Report | Benzinga

In a bid to settle thousands of lawsuits over its discontinued heartburn drug Zantac, Pfizer Inc. (NYSE:PFE) has agreed to pay up to $250 million. ...
Pfizer, Freeport-McMoRan, Vertex Pharmaceuticals And A Major Tech Stock On CNBC's 'Final Trades' | Benzinga

On CNBC's “Halftime Report Final Trades,” Joshua Brown of Ritholtz Wealth Management said under $30, Pfizer Inc. (NYSE:PFE) is a g...

Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In | Benzinga

Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028. This gr...

'Seems Low:' Elon Musk Questions Pfizer's $0 Tax Bill, But Did Tesla Pony Up To Uncle Sam? | Benzinga

Tesla CEO Elon Musk seems to think biopharma giant Pfizer, Inc. (NYSE:PFE) has dodged taxes despite high profits...
Previous 10 Next 10